Roll-over Study to Allow Continued Access to Ribociclib
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Ribociclib|DRUG: Letrozole|DRUG: Anastrozole|DRUG: Goserelin|DRUG: Tamoxifen|DRUG: Fulvestrant
Sponsor: Novartis Pharmaceuticals